Correspondence 0001437749-24-014147 from PULSE BIOSCIENCES, INC. (PLSE)
PULSE BIOSCIENCES, INC.
Date: May 1, 2024 · CIK: 0001625101 · Accession: 0001437749-24-014147
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-278494
Letter
plse20240501_corresp.htm
PULSE BIOSCIENCES, INC.
3957 Point Eden Way
Hayward, California 94545
(510) 906-4600
May 1, 2024
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Pulse Biosciences, Inc.
Registration Statement on Form S-3
File No. 333-278494
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Pulse Biosciences, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-278494) (the “Registration Statement”), so that it may become effective at 4:30 p.m. Eastern Time on May 3, 2024, or as soon thereafter as practicable.
The Registrant hereby acknowledges that:
(a) should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
(b) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
(c) the Registrant may not assert staff comments and the declaration of effectiveness of the Registration Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
We request that we be notified of such effectiveness by a telephone call to Adam Finerman, of Baker & Hostetler LLP, at (212) 589-4233 or afinerman@bakerlaw.com.
Very truly yours,
PULSE BIOSCIENCES, INC.
Show Raw Text
CORRESP 1 filename1.htm plse20240501_corresp.htm PULSE BIOSCIENCES, INC. 3957 Point Eden Way Hayward, California 94545 (510) 906-4600 May 1, 2024 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Pulse Biosciences, Inc. Registration Statement on Form S-3 File No. 333-278494 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Pulse Biosciences, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-278494) (the “Registration Statement”), so that it may become effective at 4:30 p.m. Eastern Time on May 3, 2024, or as soon thereafter as practicable. The Registrant hereby acknowledges that: (a) should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement; (b) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and (c) the Registrant may not assert staff comments and the declaration of effectiveness of the Registration Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We request that we be notified of such effectiveness by a telephone call to Adam Finerman, of Baker & Hostetler LLP, at (212) 589-4233 or afinerman@bakerlaw.com. Very truly yours, PULSE BIOSCIENCES, INC. By: /s/ Kevin P. Danahy Name: Kevin P. Danahy Title: President and Chief Executive Officer